The United Laboratories International Holdings Ltd. (TUL) and Novo Nordisk A/S (NVO) have announced promising topline results from a phase 2 trial of investigational drug UBT251 in Chinese patients with type 2 diabetes.UBT251 is a triple agonist targeting the GLP-1, GIP, and glucagon receptors (triple G) and is being co-developed by United Biotechnology, a subsidiary of United Labs, and Novo Nordisk. Triple G agonists are designed to treat type 2 diabetes and obesity. In the phase 2 trial, conducted by Uni ...